MUMBAI: In an indication of innovation in pharmaceuticals for Covid-19, Mumbai-based Glenmark may become the first company in India to offer an anti-retroviral, a class of drugs which has shown promise, and is being used as a potential treatment for the virus.
Glenmark has developed anti-retroviral (ARV) drug Favipiravir, which has shown positive results globally, and has applied for regulatory approval for trials in India, sources told TOI.
Faviparir has demonstrated good results against influenza viruses, including those that are oseltamivir-resistant, and has been approved in Japan and China. Globally, it is eit
